Back to News
Market Impact: 0.2
SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights
Source: globenewswire.com
Healthcare & Biotech
Adult and adolescent cohorts are fully enrolled in the registrational SAFEGUARD study of SAB-142. Enrollment is ongoing in the pediatric cohort (ages 5–11), with total study enrollment on track for completion in Q4 2026; no trial results were reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
More News
- We're raising our price target on Cardinal Health after another stellar quarter of profits
- Halozyme falls 6% as raised guidance fails to impress investors
- Dentsply earnings missed by $0.02, revenue fell short of estimates
- Cigna raises annual profit forecast on strength in health services unit
- US hospitals brace for tougher 2027 as coverage losses and Medicaid cuts loom
- Truist raises Zimmer Biomet stock price target on robotics progress